News

The Committee for Medicinal Products for Human Use (CHMP) concluded that the available data show an increased risk of cardiovascular adverse events for COX-2 inhibitors as a class.

Topigen’s dual-antisense compound, ASM8 targets multiple mediators and has been demonstrated in pre-clinical studies to block two major pathways of the inflammation response, thus shutting down the most

The prostate cancer study is the first trial of Aplidin in solid tumors to be carried out in the US. The objective of the study is to determine

Common chemotherapeutics that Quinamed improves or ‘chemopotentiates’ include cisplatin (Bristol-Myers Squibb’s Platinol), paclitaxel (Bristol-Myers Squibb’s Taxol), vinblastine (Eli Lilly’s Velban) and camptothecin (a trademark of the Research Triangle

According to reports, FDA safety officer David Graham told a conference that Mobic is potentially as dangerous as Vioxx in terms of cardiovascular safety risks. This alleged risk

The terms of the settlement, which remain subject to government review, provide that Teva may, under an exclusive royalty-bearing license from GSK, and on a date not later

The goals of the project are to identify and optimize A2A antagonist compounds as therapeutic candidates for Parkinson’s disease and to evaluate these novel compounds in the laboratory.

HIV infection and HIV medications are both associated with the development of neuropathy and neuropathic pain. Symptoms include burning sensations and numbness, which are similar to the neuropathies

In January, Provenge failed to achieve its primary endpoint in another phase III trial, sending Dendreon’s shares down by close to 27%. In the recent trial, however, the